What Baralgan-Nu Treats: Main Uses and Benefits

Baralgan-Nu is used for the management of symptoms related to involuntary muscle contractions, commonly referred to as spasms, in the abdominal and related areas. This medicine is a type of antispasmodic medication. Its primary purpose is to help provide symptom relief from pain and discomfort associated with these spasmodic events.

Indications include conditions such as intestinal colic, renal colic, biliary colic, and spasmodic dysmenorrhea (pain during menstruation). The medication may help by easing the smooth muscle contractions that cause this type of pain. Its use focuses on supportive comfort during these episodes.

---

Quick Fact: Relief for Spasmodic Pain

---

This information outlines the official population eligibility and non-eligibility rules for Baralgan-Nu, strictly based on authoritative government regulatory documents.

Eligibility and Non-Eligibility Status

Classification	Populations and Conditions
Use is Contraindicated	Known hypersensitivity or allergy to dicyclomine, paracetamol, or any component of the medicine. Conditions including glaucoma, myasthenia gravis, obstructive uropathy, obstructive disease of the gastrointestinal tract, severe ulcerative colitis, reflux esophagitis, severe hepatocellular (liver) insufficiency, and unstable cardiovascular status in acute hemorrhage.
Use is Not Recommended	Children under the age of 12 years (some documents specify under 10 years). Breastfeeding or nursing mothers. Patients with alcoholism or non-cirrhotic alcoholic liver disease.
Use Requires Caution	Patients with severe kidney disease, other forms of severe liver disease, certain cardiac conditions (e.g., hypertension, coronary heart disease, cardiac tachyarrhythmia), prostatic hypertrophy, and hyperthyroidism. Elderly patients are also advised caution due to increased sensitivity to anticholinergic effects.

Official regulatory documents define who cannot use this medicine through absolute contraindications, primarily targeting individuals with known allergies and those with pre-existing conditions that the drug’s components could severely exacerbate. Specific exclusions are in place for certain severe gastrointestinal, urinary tract, and ocular conditions, and use is restricted or not recommended for pediatric patients below a specified age, as well as for nursing mothers.

Interactions with other medicines and products

Official regulatory information identifies specific drug classes and substances that may interact with the active components of Baralgan-Nu (Acetaminophen and Dicycloverine).

---

Contraindicated Combinations

Combination Class	Regulatory Constraint
Other Acetaminophen Products	Contraindicated to prevent exceeding the maximum recommended daily dose and the risk of acute liver failure.
Antiglaucoma Agents	Contraindicated in patients with glaucoma as the Dicycloverine component may antagonize their effects and increase intraocular pressure.

---

Other Clinically Relevant Interactions

• Agents with Anticholinergic Activity: Combining Dicycloverine with other anticholinergic agents (e.g., certain antihistamines, MAO inhibitors, or phenothiazines) may result in additive effects, leading to an increase in anticholinergic actions.
• Anticoagulants (e.g., Warfarin): Chronic oral use of the Acetaminophen component may cause an increase in the International Normalized Ratio (INR) in patients stabilized on Warfarin, requiring monitoring.
• Gastrointestinal Motility Agents: Dicycloverine may antagonize the effects of drugs that speed up gastrointestinal motility, such as Metoclopramide.
• Antacids: Simultaneous use must be avoided as antacids are documented to interfere with the absorption of the Dicycloverine component.
• Alcohol: Consumption of three or more alcoholic drinks per day is officially documented to increase the risk of severe liver damage associated with the Acetaminophen component.

Population Considerations

The Acetaminophen component is contraindicated in patients with severe hepatic impairment due to the risk of toxicity. Caution is also noted for use in the geriatric population, who may be more susceptible to the adverse effects of Dicycloverine.

Central Attenuation of Nociceptive Signaling and Thermoregulation

This component acts predominantly in the Central Nervous System (CNS), where it selectively modulates the synthesis of prostaglandins, which are key chemical mediators in pain signaling and temperature control. By inhibiting the peroxidase site of central Cyclooxygenase (COX) enzymes, this mechanism effectively attenuates signaling and adjusts the body’s thermal set point. This targeted central modulation leads to the physiological consequences of attenuation of nociceptive signaling and adjustment of the hypothalamic thermoregulatory set point.

---

Peripheral Antispasmodic Blockade

The Dicycloverine mechanism involves Peripheral Nervous System action as a non-selective competitive antagonist of Muscarinic Acetylcholine Receptors (M1, M2, M3). Blocking the acetylcholine signal at the smooth muscle cell surface interrupts the resulting intracellular calcium cascade that initiates contraction. This disruption leads to the physiological effect of spasmolysis—the cessation of cholinergic-induced smooth muscle contraction.

---

Complementary Dual-System Engagement

The resulting physiological change stems from the additive effect of engaging these two distinct systems simultaneously. The central mechanism modulates nociceptive signaling, while the peripheral mechanism disrupts cholinergic-mediated hypermotility. This complementary action ensures concurrent modulation of nociceptive signaling and smooth muscle tone.

How to Use Baralgan-Nu

The administration of Baralgan-Nu is governed by instructions defining the approved route, frequency, and specific handling requirements for the fixed-dose combination product. This medicine is strictly administered via the oral route as a tablet.

---

Standard Administration Principles

The tablet must be swallowed whole with water and should not be crushed, chewed, or broken. Administration is not contingent upon mealtimes, and the medicine may be taken with or without food. As Baralgan-Nu is utilized for symptomatic relief, its use follows an intermittent pattern tied to the duration of the acute episode, not a long-term maintenance schedule.

---

Official Dosing Regimen

The standard dose is one tablet per administration. The maximum prescribed dosing frequency is established at up to four times a day (QID), though some labels specify three times a day. The limits on total daily intake necessitate strict caution regarding the 500 mg Paracetamol component to prevent co-administration with other Paracetamol-containing products. If a dose is missed, instructions advise taking the next scheduled dose at the usual time and not taking a double dose to compensate.

---

Age Constraints

Usage is subject to a clear age constraint, as the formulation is not to be used in children below 12 years of age.

---

Research evidence / Overview of studies for Baralgan-Nu

This section summarizes the official research evidence that exists for Baralgan-Nu, focusing on the types of studies, patient populations, and outcomes evaluated by researchers and regulatory bodies. The evidence described is primarily derived from Randomized Controlled Trials (RCTs), systematic reviews, and official regulatory summaries of the active components and fixed-dose combinations.

---

Evidence for use in Intestinal Colic and Abdominal Cramping

Research examined the use of antispasmodic agents, either alone or in combinations, in adult populations with conditions characterized by fluctuating or episodic manifestations such as functional bowel disorders. The primary outcomes related to physical discomfort that researchers monitored were patient reports of pain intensity and the frequency of pain episodes over the study duration. Findings help contextualize how patients reported their experience. The overall certainty of the evidence for the specific fixed-dose combination remains low to moderate because many key trials for the antispasmodic component are older and involved small sample sizes.

---

Research Focus on Acute Spasmodic Pain (e.g., Renal Colic)

Studies focused on conditions involving sudden, severe pain associated with smooth muscle spasms, such as renal colic, where the active components were evaluated in studies focused on immediate symptom management. These studies are typically Very Short-term. Researchers monitored outcomes describing episodic or acute changes in pain, specifically how rapidly changes in patient-reported pain intensity were observed and the recorded use of supplemental pain medication during the first few hours of the episode. The evidence level for this application of the combination class is broadly assessed as Moderate.

---

What is Still Uncertain About Baralgan-Nu Research

While the individual components—Acetaminophen for pain and Dicycloverine for muscle spasm—are widely studied, the primary gap in the research involves the fixed-dose combination product itself. The sample sizes were modest in many of the foundational studies, and comparative evidence is lacking for certain uses. Research indicates that certainty remains low regarding the broad application and long-term effects.

Key Studies & References

1. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care (NICE Guideline CG61)
2. Pharmacologic interventions to treat renal colic pain in acute stone episodes (Systematic Review)

How to Store and Dispose of Baralgan-Nu

The storage and disposal of Baralgan-Nu Tablet must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

---

Storage Requirements

• Temperature and Protection: The medicine must be stored at a temperature not exceeding 30 C. It is mandatory to store the product in a cool and dry place, protected from both light and moisture.
• Child Safety: A crucial constraint is to keep Baralgan-Nu out of the sight and reach of children to prevent accidental ingestion.
• Stability: The product maintains its stability until the printed expiry date, provided these environmental and temperature conditions are strictly met.

---

Disposal Instructions

• Discarding: Unused or expired Baralgan-Nu Tablet must be safely discarded when no longer needed.
• Prevention of Consumption: Disposal procedures must ensure that the medicine is not consumed by pets, children, or other people.